A hydration program to ease side effects of GLP-1 diabetes and weight-loss medicines
Tests a hydration program in adults starting GLP-1 medicines for obesity or type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
Key facts
- Where
- Buffalo, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07641361, who can take part
Where in United States
- State University of New York at Buffalo, South CampusBuffalo, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- State University of New York at Buffalo
- Trial code
- NCT07641361
- Record updated
- 2 October 2026
- Original description
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.Read full original descriptionShow less
Hydration Intervention to Address Dehydration Associated With Use of GLP-1 Based Medications
This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.
Inclusion: Adults aged 18-60; Recently prescribed a GLP-1RA (within one week of prescription); Fluent in English; Willing to complete the study protocol.
Exclusion: People with cardiac implants; Children and adults > 60 years of age; Those not taking a GLP-1RA; Those who have been on a GLP-1RA longer than one week; Not fluent in English; Those who are pregnant or planning on becoming pregnant during the duration of the study; Unwilling to comply with study protocol.